Form 4: Health Catalyst GC Sells Shares Under 10b5-1 Plan

Health Catalyst's General Counsel, Benjamin Landry, sold 6,175 shares of common stock for $3.353 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Benjamin Landry, General Counsel of Health Catalyst, Inc. (HCAT), reported a sale of common stock.
• The transaction involved the disposition of 6,175 shares of Health Catalyst common stock.
• The shares were sold at a price of $3.353 per share.
• Following this transaction, Mr. Landry beneficially owns 141,812 shares of common stock.
• The sale was executed on September 5, 2025, as part of a Rule 10b5-1 trading plan adopted on March 1, 2025.

Sentiment

Score: 5

Explanation: A neutral score. While an insider sale typically carries a slight negative sentiment, the execution under a pre-arranged 10b5-1 plan mitigates concerns about discretionary selling based on new negative information. It's a routine liquidity event.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled, non-discretionary transaction rather than a reaction to new material non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct equity stake in the company.

Stakeholder Impact

• Shareholders might perceive a slight negative signal from an insider sale, though the 10b5-1 plan mitigates concerns about discretionary selling.

Key Dates

Recommendation

The filing reports a routine insider sale under a pre-arranged 10b5-1 plan, which does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this transaction. Investors should consider broader company performance and market conditions.

Keywords

Health Catalyst, HCAT, Benjamin Landry, Insider Trading, Form 4, 10b5-1 Plan, Stock Sale, General Counsel, Equity Transaction